Pharmaceuticals Financial News

It said «The companies see only marginal impact and no major disruption to US business from the planned US tariffs (10-25 per cent)». The US remains a key market for Indian CDMO players, with exports worth approximately USD 9-10 billion annually. While the tariff proposal has raised concerns, Indian firms expect only a marginal impact on their business.

Macrotech Developers, has entered into an agreement to acquire a land parcel spread over 3.4 acres in Mumbai's western suburb Jogeshwari West from pharmaceutical company Unichem Laboratories for over '279 crore. The land parcel at Prabhat Estate off Swami Vivekananda Road houses an office building spread over 82,000 sq ft, which was the registered office of the company until now. While the deal is yet to be inked and registered, Unichem's board of directors have approved the plan to monetise this land parcel.

Aveo Pharmaceuticals said the company has been issued stop-production notice for non-compliance with manufacturing standards and not for export of opioid-based drugs to West African nations. Arvind Sharma, its managing director, also told ET's Teena Thacker and Vikas Dandekar that the company has valid product permissions from the state food and drug administrator for Tafradol, a combination of Tapentadol and Carisoprodol. Edited excerpts: What is the status of allegations of exports of opioids to West African nations? The allegations that our products are narcotics opioids are false. All our products are legitimate, licensed pharmaceuticals sold under valid prescriptions in numerous countries.

Sun Pharmaceuticals on Monday announced that it is set to acquire Checkpoint Therapeutics, an immunotherapy and targeted oncology company, for $355 million. The transaction is expected to be completed in the second calendar quarter of 2025. Checkpoint is a Nasdaq-listed commercial-stage company focused on developing novel treatments for patients with solid tumor cancers. The company has the license from the U.S. Food & Drug Administration (FDA) for UNLOXCYT (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Dilip Shanghvi, Chairman & Managing Director of Sun Pharma, said, “Combining UNLOXCYT, an FDAapproved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, with Sun Pharma’s global presence means patients with cSCC may soon have access to an important, new treatment option. The acquisition further bolsters our innovative portfolio in onco-derm therapy.”

Subscribe to enjoy similar stories. India's drugmakers saw healthy revenue growth across all therapies in February as they debuted new drugs and raised prices, an industry report showed. Sales in the domestic pharmaceutical market in February touched ₹18,781 crore, up 7.5% from a year earlier, data from B2B commerce platform Pharmarack showed.

The automobile sector, on the other hand, is expected to have a very minimal impact owing to the US being a small export market. Terming India as a very high tariff nation, US President Donald Trump has said that reciprocal tariffs on countries that impose levies on American goods will kick in on April 2.

Subscribe to enjoy similar stories. SCIENTISTS LOOKING to remove carbon dioxide (CO2) from the air cleanly and cheaply have long been interested in metal-organic frameworks, or MOFs: gigantic, sponge-like molecules that can be precisely engineered to capture the gas and then release it on command. Made of metal ions held together by compounds containing carbon, MOFs come in a dizzying array of structures, each with its own distinct properties.

volatility into global stock markets, with India finding itself in the crosshairs of the U.S. president’s push for trade realignment. With India’s effective tariff rate on U.S. goods at 9.5%, compared to the 3% that the U.S. imposes on Indian goods, the threat of reciprocal tariffs looms large, sparking concerns across key industries, from automobiles and pharmaceuticals to textiles and steel. Even after this week's relief rally, Nifty is still down around 14% from peak while smallcaps and microcaps are locked in bear market territory as FIIs have pulled out over $15 billion from Indian stocks in 2025 alone.

Laurus Labs will be in focus on Friday after the company approved an investment of Rs 83.3 crore in KRKA Pharma Pvt Ltd, a joint venture. In addition, KRKA d.d., Novo Mesto, Slovenia (the co-venturer), will invest Rs 86.7 crore in KRKA Pharma, thereby maintaining the current shareholding ratio of 51:49 between KRKA d.d., Novo Mesto, and Laurus Labs.

Subscribe to enjoy similar stories. New Delhi: A group of trade experts advising the government on its trade negotiations with the Donald Trump administration has recommended that India prepare to levy tit-for-tat tariffs on American goods that enjoy significant market access in India and that contribute to a sizeable US trade surplus in these product categories.

Subscribe to enjoy similar stories. New Delhi: As Indian and US negotiators huddle in Washington to iron out issues in a potential trade deal, one of the key areas that has emerged is petrochemical trade, three people aware of the matter said on the condition of anonymity.

trade and commercial ties with India has urged both countries to focus on normalising trade and business relationship between them for the welfare of the people of both sides. In a letter to the Pakistan-India Joint Business Forum (PIJBF) Wednesday, the Pak-India Business Council chairman Noor Muhammad Kasuri asked it to play its due role in creating circumstances where the two countries may save approximately USD 10 billion in the fields of energy sector, petroleum products, raw material for pharmaceutical industry, consumers' goods, cotton items and infrastructure development. He said the businessmen of both countries suffered due to passive ties for the last six years. «Strenuous efforts should be made to create a conducive atmosphere where businessmen of both the countries may avail trade and business opportunities present in their respective countries,» he said.

Glenmark Pharmaceuticals Ltd.(up 3.06 per cent), Aurobindo Pharma Ltd.(up 2.91 per cent), Laurus Labs Ltd.(up 2.0 per cent), Ipca Laboratories Ltd.(up 1.84 per cent) and Lupin Ltd.(up 1.63 per cent) were among the top gainers.

Kenneth Andrade, the ace investor known for his high-conviction calls, looks for businesses early into a business cycle as part of his investment philosophy. The chief investment officer of Old Bridge Capital Asset Management observed that India's market capitalisation to GDP ratio is 130%, which still indicates overvaluation. However, he still sees pockets of opportunity in the market. Andrade shared his market outlook recently during a presentation on his fund's position and where he sees investment opportunities.

Natco Pharma Ltd.(up 3.12 per cent), Glenmark Pharmaceuticals Ltd.(up 1.03 per cent), Lupin Ltd.(up 0.57 per cent) and Sun Pharmaceutical Industries Ltd.(up 0.43 per cent) were among the top gainers.

Subscribe to enjoy similar stories. Piramal Enterprises Ltd is planning to sell its holdings in Shriram Group's insurance ventures for ₹4,000-5,000 crore, two people aware of the matter said, as it looks to sharpen focus on its core lending business. The Ajay Piramal-led group holds about 15% in Shriram General Insurance Co.

Glenmark Pharmaceuticals is recalling close to 15 lakh bottles of a generic medication used in the treatment of attention deficit hyperactivity disorder in the US market, according to the US health regulator. Glenmark Pharmaceuticals Inc, USA, a subsidiary of the Mumbai-based drug maker, is recalling around 14.76 lakh bottles of Atomoxetine Capsules in multiple strengths. The company is recalling the affected lot due to «CGMP Deviations», the US Food and Drug Administration (USFDA) said in its latest Enforcement Report. The recall is due to «presence of N-Nitroso Atomoxetine impurity above the FDA recommended limit,» it added.

pharmaceutical industry say levying tariffs may make generic drugs marginally costlier for the US patients and even lead to drug shortages. Dilip Shanghvi, chairman and managing director at Sun Pharma, India's largest drug maker by sales and market cap, told an industry gathering that his company sells products between $1 and $5 per bottle in the US and a tariff of 10% or 25% may marginally change that cost. «Possibly it will not justify relocating manufacturing,» Shanghvi said, responding to Trump's frenetic calls to either set up manufacturing bases in the US or face tariffs. He added the profit margins for drugs sold in the US are so low that the ability to absorb tariffs is limited. «Ultimately it will get passed on to the consumers,» he noted. For FY24, Sun Pharma had 32% of its total sales of ₹47,800 crore from the US, a notch higher than 31% that came from its home market India.

Piramal Enterprises said in an exchange filing on Friday that it had received a tax demand of 15.02 billion rupees (nearly $172 million) for the sale of its pharmaceutical business to Piramal Pharma in fiscal year 2021. A tax office in the state of Maharashtra has asked the financial services company to pay 18% Goods and Services Tax (GST) on the deal, the latter said in the filing. The tax bill amounts to about 15% of its revenue for the fiscal year ended March 31, 2024. Piramal Enterprises said it has solid grounds to challenge the «unjustified» demand.

CDSCO) is looking at a revamp of the process of granting of No Objection Certificates (NOCs) for the export of unapproved drugs, a move that is aimed at reducing pressure on manpower and boosting regulatory efficiency.

Subscribe to enjoy similar stories. MUMBAI : The Central Drugs Standard Control Organisation (CDSCO) is in the process of creating guidelines to regulate cell and gene therapies and upgrading the framework to regulate biosimilars, as the Indian industry moves towards innovations in the space, Drugs Controller General of India (DCGI) Rajeev Raghuvanshi said on Thursday. Raghuvanshi, who was speaking on the sidelines of the Indian Pharmaceutical Alliance’s (IPA) Global Pharmaceutical Quality Summit 2025, said that while the country's top drug regulator had been focusing on operational efficiency, it's also looking closely at newer areas.